Current evolved Cas9 (CRISPR) variants are highly efficient and relatively unconstrained in terms of their human genome targeting coverage. Smaller nucleases and higher targeting specificity would be useful. But therapeutic use is mostly limited by delivery.
This seems revolve around a known retron-like reverse transcriptase. A sober framing would be something like: Claude identified a previously undescribed genomic arrangement around a known reverse transcriptase. Not all that sexy.
For now, this is mostly a story about how AI can be used to parse existing data to discover new biology (which is fantastic!).
This seems revolve around a known retron-like reverse transcriptase. A sober framing would be something like: Claude identified a previously undescribed genomic arrangement around a known reverse transcriptase. Not all that sexy.
For now, this is mostly a story about how AI can be used to parse existing data to discover new biology (which is fantastic!).